Tesamorelin 5mg

Tesamorelin and regional fat metabolism

Tesamorelin 5mg is a modified GHRH peptide investigated for its effects on the GH/IGF-I axis and regional fat distribution. Alongside visceral-fat studies, a distinct line of clinical research has examined liver fat in people with HIV.

Liver-fat investigations

A randomised, double-blind trial in people with HIV and fatty liver disease reported a greater reduction in hepatic fat with tesamorelin than with placebo. Researchers also assessed histology and metabolic measures, extending the investigation beyond an external measure of body composition.

A later analysis focused on participants receiving integrase-inhibitor-based HIV therapy. This adds clinically relevant context about the treatment background of the participants, while remaining tied to the same specific research population.

Understanding the scope of the findings

These studies support interest in the relationship between GHRH signalling and regional fat metabolism. Changes in liver fat are meaningful study outcomes, but do not by themselves establish long-term liver-disease or survival benefits.

Egrifta medicines contain tesamorelin and have formulation-specific prescribing information. This 5mg research vial is not identified as an Egrifta formulation. It is a quantity variant of the same named compound offered at 2mg, rather than evidence of a different mechanism or greater clinical effectiveness.

Also known as / branded as

• Egrifta (brand family of tesamorelin medicines)
• Egrifta SV (specific medicine formulation)
• Egrifta WR (specific medicine formulation)